The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Open accessAbstract
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and apalutamide which target androgen receptor (AR) signaling, radium-223 dichloride for reduction of bone metastases, sipuleucel-T immunotherapy and taxane-based chemotherapy. Adding abiraterone acetate to androgen deprivation therapy (ADT) in order to achieve complete androgen blockade has proven highly beneficial for treatment of locally advanced prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC). Also, ADT together with docetaxel treatment showed significant benefit in mHSPC. Ongoing clinical trials for different subgroups of prostate cancer patients include the evaluation of the second-generation AR antagonists enzalutamide, apalutamide and darolutamide, of inhibitors of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway, of inhibitors of DNA damage response, of targeted alpha therapy and of prostate-specific membrane antigen (PSMA) targeting approaches. Advanced clinical studies with immune checkpoint inhibitors have shown limited benefits in prostate cancer and more trials are needed to demonstrate efficacy. The identification of improved, personalized treatments will be much supported by the major progress recently made in the molecular characterization of early- and late-stage prostate cancer using “omics” technologies. This has already led to novel classifications of prostate tumors based on gene expression profiles and mutation status, and should greatly help in the choice of novel targeted therapies best tailored to the needs of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 3×
“Importantly, potential driver mutations in MLL gene family members have been identified in prostate cancer samples by exome sequencing analysis [28,96].”
BackgroundAbiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
Metzger, E., Wissmann, M., Yin, N., Müller, J. M., Schneider, R., Peters, A. H. F. M., Günther, T., Buettner, R., & Schüle, R. (2005) · Nature · doi:10.1038/nature04020 · Cited by 1,733
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group, Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E., Brewer, D. S., Kallio, H. M. L., Högnäs, G., et al. (2015) · Nature · doi:10.1038/nature14347 · Cited by 1,388
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344 · cited 3×
“In addition, it strongly improves metastasis-free survival (MFS) in high-risk non-metastatic CRPC (nmCRPC) patients.”
BackgroundPunctuated Evolution of Prostate Cancer Genomes
Baca, S. C., Prandi, D., Lawrence, M. S., Mosquera, J. M., Romanel, A., Drier, Y., Park, K., Kitabayashi, N., MacDonald, T. Y., Ghandi, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.021 · Cited by 1,320
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,234
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · cited 1×
“A genetically engineered mouse model with prostate-specific deletion of the Pten gene recapitulates the different disease stages observed in humans [54].”
BackgroundTherapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
The long tail of oncogenic drivers in prostate cancer
PCF/SU2C International Prostate Cancer Dream Team, Armenia, J., Wankowicz, S. A. M., Liu, D., Gao, J., Kundra, R., Reznik, E., Chatila, W. K., Chakravarty, D., Han, G. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0078-z · Cited by 867
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Lasko, L. M., Jakob, C. G., Edalji, R. P., Qiu, W., Montgomery, D., Digiammarino, E. L., Hansen, T. M., Risi, R. M., Frey, R., Manaves, V., et al. (2017) · Nature · doi:10.1038/nature24028 · Cited by 858
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744 · cited 2×
“These tumors often exhibit active FGF receptor and MAPK signaling to bypass the AR pathway for sustained prostate cancer growth, and initial preclinical experiments with selective inhibitors show in vitro and in vivo efficacy in double-negative prostate cancer models [32].”
BackgroundFirst FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S., Keegan, P., & Pazdur, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.006 · Cited by 516
Annala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
Tracking the clonal origin of lethal prostate cancer
Haffner, M. C., Mosbruger, T., Esopi, D. M., Fedor, H., Heaphy, C. M., Walker, D. A., Adejola, N., Gürel, M., Hicks, J., Meeker, A. K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70354 · Cited by 497
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Kratochwil, C., Bruchertseifer, F., Rathke, H., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 421
Androgen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
Moilanen, A.-M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P. S., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 379
Tumor clone dynamics in lethal prostate cancer
Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., Prandi, D., Lorente, D., Frenel, J.-S., Pezaro, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009448 · Cited by 340
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
Qi, W., Zhao, K., Gu, J., Huang, Y., Wang, Y., Zhang, H., Zhang, M., Zhang, J., Yu, Z., Li, L., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2304 · Cited by 316 · cited 2×
“EED is another core component of the PRC2 complex and its inhibitor MAK683, which is related to EED226 [94], has recently entered a clinical phase 1 study which includes prostate cancer patients [95].”
BackgroundZhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., Speers, C., Cooperberg, M. R., Kim, W., Ryan, C. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0751 · Cited by 308
Zhang, P., Wang, D., Zhao, Y., Ren, S., Gao, K., Ye, Z., Wang, S., Pan, C.-W., Zhu, Y., Yan, Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4379 · Cited by 297
Schwartz, S., Wongvipat, J., Trigwell, C. B., Hancox, U., Carver, B. S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.008 · Cited by 246
The Mutational Landscape of Prostate Cancer
Barbieri, C. E., Bangma, C. H., Bjartell, A., Catto, J. W. F., Culig, Z., Grönberg, H., Luo, J., Visakorpi, T., & Rubin, M. A. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.029 · Cited by 239
Current treatment strategies for advanced prostate cancer
Komura, K., Sweeney, C. J., Inamoto, T., Ibuki, N., Azuma, H., & Kantoff, P. W. (2018) · International Journal of Urology · doi:10.1111/iju.13512 · Cited by 239
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
Sehrawat, A., Gao, L., Wang, Y., Bankhead, A., McWeeney, S. K., King, C. J., Schwartzman, J., Urrutia, J., Bisson, W. H., Coleman, D. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719168115 · Cited by 230
Wallin, J. J., Edgar, K. A., Guan, J., Berry, M., Prior, W. W., Lee, L., Lesnick, J. D., Lewis, C., Nonomiya, J., Pang, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0446 · Cited by 229
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 223
Di Micco, R., Fontanals-Cirera, B., Low, V., Ntziachristos, P., Yuen, S. K., Lovell, C. D., Dolgalev, I., Yonekubo, Y., Zhang, G., Rusinova, E., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.055 · Cited by 217
Targeting the MLL complex in castration-resistant prostate cancer
Malik, R., Khan, A. P., Asangani, I. A., Cieślik, M., Prensner, J. R., Wang, X., Iyer, M. K., Jiang, X., Borkin, D., Escara-Wilke, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3830 · Cited by 210
Post-translational modifications of steroid receptors
Faus, H., & Haendler, B. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.07.082 · Cited by 209
Self-citationPasero, C., Gravis, G., Guerin, M., Granjeaud, S., Thomassin-Piana, J., Rocchi, P., Paciencia-Gros, M., Poizat, F., Bentobji, M., Azario-Cheillan, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1965 · Cited by 209
Prostate cancer, PI3K, PTEN and prognosis
Wise, H. M., Hermida, M. A., & Leslie, N. R. (2017) · Clinical Science · doi:10.1042/cs20160026 · Cited by 206
Hussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y.-M., Robinson, D., Lonigro, R. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7310 · Cited by 206
Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
Sumanasuriya, S., & De Bono, J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030635 · Cited by 203
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
You, S., Knudsen, B. S., Erho, N., Alshalalfa, M., Takhar, M., Al-deen Ashab, H., Davicioni, E., Karnes, R. J., Klein, E. A., Den, R. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0902 · Cited by 202
Mitsiades, N., Sung, C. C., Schultz, N., Danila, D. C., He, B., Eedunuri, V. K., Fleisher, M., Sander, C., Sawyers, C. L., & Scher, H. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1335 · Cited by 197
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Coutinho, I., Day, T. K., Tilley, W. D., & Selth, L. A. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-16-0422 · Cited by 194
Structure of the homodimeric androgen receptor ligand-binding domain
Nadal, M., Prekovic, S., Gallastegui, N., Helsen, C., Abella, M., Zielinska, K., Gay, M., Vilaseca, M., Taulès, M., Houtsmuller, A. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms14388 · Cited by 193 · cited 1×
“In the cell nucleus, the dimerized AR recognizes cognate DNA response elements in regulatory regions located in proximal or more distal intra- and intergenic regions of androgen target genes [4,5].”
BackgroundParker, C. C., Pascoe, S., Chodacki, A., O'Sullivan, J. M., Germá, J. R., O’Bryan-Tear, C. G., Haider, T., & Hoskin, P. (2013) · European Urology · doi:10.1016/j.eururo.2012.09.008 · Cited by 188
Kron, K. J., Murison, A., Zhou, S., Huang, V., Yamaguchi, T. N., Shiah, Y.-J., Fraser, M., van der Kwast, T., Boutros, P. C., Bristow, R. G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3930 · Cited by 187
A Systematic Review of Histone Lysine‐Specific Demethylase 1 and Its Inhibitors
Zheng, Y., Ma, J., Wang, Z., Li, J., Jiang, B., Zhou, W., Shi, X., Wang, X., Zhao, W., & Liu, H. (2015) · Medicinal Research Reviews · doi:10.1002/med.21350 · Cited by 186
Janouskova, H., El Tekle, G., Bellini, E., Udeshi, N. D., Rinaldi, A., Ulbricht, A., Bernasocchi, T., Civenni, G., Losa, M., Svinkina, T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4372 · Cited by 186
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Wyce, A., Degenhardt, Y., Bai, Y., Le, B., Korenchuk, S., Crouthamel, M.-C., McHugh, C. F., Vessella, R., Creasy, C. L., Tummino, P. J., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1572 · Cited by 179
Suominen, M. I., Fagerlund, K. M., Rissanen, J. P., Konkol, Y. M., Morko, J. P., Peng, Z., Alhoniemi, E. J., Laine, S. K., Corey, E., Mumberg, D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2955 · Cited by 177
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
Wadosky, K. M., & Koochekpour, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10901 · Cited by 174
Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T., Pérez-Fidalgo, J. A., Morales-Barrera, R., Sanchis-García, J. M., Musib, L., Budha, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 172
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
Kluetz, P. G., Pierce, W., Maher, V. E., Zhang, H., Tang, S., Song, P., Liu, Q., Haber, M. T., Leutzinger, E. E., Al-Hakim, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2665 · Cited by 170
Targeting BET Bromodomains for Cancer Treatment
Jung, M., Gelato, K. A., Fernández-Montalván, A., Siegel, S., & Haendler, B. (2015) · Epigenomics · doi:10.2217/epi.14.91 · Cited by 163
Self-citationGarapaty, S., Nasveschuk, C. G., Gagnon, A., Chan, E. Y., Sandy, P., Busby, J., Balasubramanian, S., Campbell, R., Zhao, F., Bergeron, L., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.013 · Cited by 163
The Proteome of Primary Prostate Cancer
Iglesias-Gato, D., Wikström, P., Tyanova, S., Lavallee, C., Thysell, E., Carlsson, J., Hägglöf, C., Cox, J., Andrén, O., Stattin, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.053 · Cited by 163
AR Signaling and the PI3K Pathway in Prostate Cancer
Crumbaker, M., Khoja, L., & Joshua, A. (2017) · Cancers · doi:10.3390/cancers9040034 · Cited by 162
Rydzewska, L. H. M., Burdett, S., Vale, C. L., Clarke, N. W., Fizazi, K. S., Kheoh, T. S., Mason, M. D., Miladinović, B., James, N. D., Parmar, M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.003 · Cited by 162
EZH2, an epigenetic driver of prostate cancer
Yang, Y. A., & Yu, J. (2013) · Protein & Cell · doi:10.1007/s13238-013-2093-2 · Cited by 161
Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
Thadani‐Mulero, M., Nanus, D. M., & Giannakakou, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0783 · Cited by 158
Chan, S. C., Selth, L. A., Li, Y., Nyquist, M. D., Lu, M., Bradner, J. E., Raj, G. V., Tilley, W. D., & Dehm, S. M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv262 · Cited by 158
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 157
Posttranslational Modification of the Androgen Receptor in Prostate Cancer
der Steen, T. V., Tindall, D. J., & Huang, H. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714833 · Cited by 156
Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0314 · Cited by 153
Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies
Lima, A. R., Bastos, M. D. L., Carvalho, M. C., & de Pinho, P. G. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.05.004 · Cited by 144
Stepwise androgen receptor dimerization
van Royen, M. E., van Cappellen, W. A., de Vos, C., Houtsmuller, A. B., & Trapman, J. (2012) · Journal of Cell Science · doi:10.1242/jcs.096792 · Cited by 143
Glucose Metabolism in the Progression of Prostate Cancer
Cutruzzolà, F., Giardina, G., Marani, M., Macone, A., Paiardini, A., Rinaldo, S., & Paone, A. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00097 · Cited by 143
Börno, S. T., Fischer, A., Kerick, M., Fälth, M., Laible, M., Brase, J. C., Kuner, R., Dahl, A., Grimm, C., Sayanjali, B., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0041 · Cited by 138
Butler, D. E., Marlein, C. R., Walker, H. F., Frame, F. M., Mann, V. M., Simms, M. S., Davies, B. R., Collins, A. T., & Maitland, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18082 · Cited by 138
Advances Toward Lsd1 Inhibitors for Cancer Therapy
Fu, X., Zhang, P., & Yu, B. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0068 · Cited by 135
The importance of DNA methylation in prostate cancer development.
Massie, C., Mills, I., & Lynch, A. G. (2017) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.009 · Cited by 132
Shenoy, T., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx165 · Cited by 129
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness
Kari, V., Mansour, W. Y., Raul, S. K., Baumgart, S. J., Mund, A., Grade, M., Sirma, H., Simon, R., Will, H., Dobbelstein, M., et al. (2016) · EMBO Reports · doi:10.15252/embr.201642352 · Cited by 126
Self-citationRevisiting the role of Wnt/β-catenin signaling in prostate cancer
Schneider, J. A., & Logan, S. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.008 · Cited by 121
Yang, Y. C., Banuelos, C. A., Mawji, N. R., Wang, J., Kato, M., Haile, S., McEwan, I. J., Plymate, S. R., & Sadar, M. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2901 · Cited by 118
Differentiation of human tumors from nonmalignant tissue by natural‐abundance 13C NMR spectroscopy
Halliday, K. R., Fenoglio‐Preiser, C., & Sillerud, L. O. (1988) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910070403 · Cited by 116
Ylitalo, E. B., Thysell, E., Jernberg, E., Lundholm, M., Crnalic, S., Egevad, L., Stattin, P. E., Widmark, A., Bergh, A. R. J., & Wikström, P. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.033 · Cited by 116
Borgmann, H., Lallous, N., Özistanbullu, D., Beraldi, E., Paul, N., Dalal, K., Fazli, L., Haferkamp, A., Lejeune, P., Cherkasov, A. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.012 · Cited by 114
DNA methylation and histone modifications as epigenetic regulation in prostate cancer
Nowacka‐Zawisza, M., & Wiśnik, E. (2017) · Oncology Reports · doi:10.3892/or.2017.5972 · Cited by 113
Marques, R. B., Aghai, A., de Ridder, C. M. A., Stuurman, D. C., Hoeben, S. A. H., Boer, A., Ellston, R. P. A., Barry, S. T., Davies, B. R., Trapman, J., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.053 · Cited by 108
Targeting Fibroblast Growth Factor Pathways in Prostate Cancer
Corn, P. G., Wang, F., McKeehan, W. L., & Navone, N. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1550 · Cited by 107
Murga, J. D., Moorji, S. M., Han, A. Q., Magargal, W. W., DiPippo, V. A., & Olson, W. C. (2014) · The Prostate · doi:10.1002/pros.22910 · Cited by 103
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Wang, X., Qiao, Y., Asangani, I. A., Ateeq, B., Poliakov, A., Cieslik, M. P., Pitchiaya, S., Chakravarthi, B. V. S. K., Cao, X., Jing, X., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.017 · Cited by 101
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression
Liang, Y., Ahmed, M., Guo, H., Soares, F., Hua, J. T., Gao, S., Lu, C., Poon, C., Han, W., Langstein, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0496 · Cited by 101
Wang, L., Dehm, S. M., Hillman, D. W., Sicotte, H., Tan, W. W., Gormley, M., Bhargava, V., Jiménez, R. E., Xie, F., Yin, P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx689 · Cited by 99
Chee, K. G., Longmate, J., Quinn, D. I., Chatta, G. S., Pinski, J., Twardowski, P. W., Pan, C.-X., Cambio, A., Evans, C. P., Gandara, D. R., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.031 · Cited by 95
Rathkopf, D. E., Antonarakis, E. S., Shore, N. D., Tutrone, R. F., Jr., Alumkal, J. J., Ryan, C. J., Saleh, M. N., Hauke, R. J., Bandekar, R. R., Maneval, E. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2509 · Cited by 94
Hancox, U. J., Cosulich, S. C., Hanson, L. L., Trigwell, C. B., Lenaghan, C., Ellston, R. P. A., Dry, H., Crafter, C., Barlaam, B. C., Fitzek, M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0406 · Cited by 93
ETS fusion genes in prostate cancer
Tandefelt, D. G., Boormans, J. L., Hermans, K. G., & Trapman, J. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0390 · Cited by 92
Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis
Suominen, M. I., Rissanen, J. P., Käkönen, R. S., Fagerlund, K. M., Alhoniemi, E. J., Mumberg, D., Ziegelbauer, K. B., Halleen, J. M., Käkönen, S.-M., & Scholz, A. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt116 · Cited by 91
Malamas, A. S., Gameiro, S. R., Knudson, K. M., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.13520 · Cited by 91
Massard, C., Chi, K. N., Castellano, D., Bono, J. S. D., Gravis, G., Dirix, L. Y., Machiels, J., Mita, A. C., Mellado, B., Turri, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.024 · Cited by 91
Karanika, S., Karantanos, T., Li, L., Wang, J., Park, S., Yang, G., Zuo, X., Song, J. H., Maity, S. N., Manyam, G. C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.072 · Cited by 89
Moreira, R. B., Debiasi, M., Francini, E., Nuzzo, P. V., de Velasco, G., Maluf, F. C., Fay, A. P., Joaquim Bellmunt, B., Choueiri, T. K., & Schutz, F. A. B. (2017) · Oncotarget · doi:10.18632/oncotarget.20028 · Cited by 89
Antonarakis, E. S., Chandhasin, C., Osbourne, E., Luo, J., Sadar, M. D., & Perabo, F. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0161 · Cited by 82
Canesin, G., Axelsson, S. E., Hellsten, R., Krzyzanowska, A., Prasad, C. P., Bjartell, A. S., & Andersson, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184418 · Cited by 80
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Fizazi, K. S., Albiges, L. K., Loriot, Y., & Massard, C. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1081566 · Cited by 79
Priemer, D. S., Montironi, R., Wang, L., Williamson, S. R., Antonio Lopez-beltran, B., & Liang Cheng, C. (2016) · Endocrine Pathology · doi:10.1007/s12022-016-9421-z · Cited by 79
Treatment options for localized prostate cancer.
Keyes, M., Crook, J. M., Morton, G., Vigneault, É., Usmani, N., & Morris, W. (2013) · Europe PMC (PubMed Central) · Cited by 78
Hahn, P., Smith, I. C., Leboldus, L., Littman, C. D., Somorjai, R. L., & Bezabeh, T. (1997) · PubMed · Cited by 76
Munuganti, R. S. N., Hassona, M. D. H., Leblanc, E., Frewin, K., Singh, K., Ma, D., Ban, F., Hsing, M., Adomat, H. H., Lallous, N., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.012 · Cited by 76
Current approaches to incorporation of radium-223 in clinical practice
Parker, C. C., Heidenreich, A., Nilsson, S. F., & Shore, N. D. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0020-y · Cited by 76
Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer
Čulig, Z. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25099 · Cited by 72
Bakht, M. K., Oh, S. W., Youn, H., Cheon, G. J., Kwak, C. H., & Kang, K. W. (2016) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-016-0439-4 · Cited by 71
A comprehensive review of immunotherapies in prostate cancer
Maia, M. C., & Hansen, A. R. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.026 · Cited by 71
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Statz, C. M., Patterson, S. E., & Mockus, S. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0453-6 · Cited by 70
Androgen receptor-mediated gene repression
Grosse, A., Bartsch, S., & Baniahmad, A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.032 · Cited by 69
Darolutamide (ODM-201) for the treatment of prostate cancer
Shore, N. D. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1329820 · Cited by 68
Kirk, J. S., Schaarschuch, K., Dalimov, Z., Lasorsa, E., Ku, S., Ramakrishnan, S., Hu, Q., Azabdaftari, G., Wang, J., Пили, Р., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3077 · Cited by 65
Faivre, E. J., Wilcox, D. M., Li, X., Hessler, P., Torrent, M., He, W. A., Uziel, T., Albert, D. H., McDaniel, K. F., Kati, W. M., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0221 · Cited by 65
PARP Inhibitors in Prostate Cancer
Geethakumari, P. R., Schiewer, M. J., Knudsen, K. E., & Kelly, W. K. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0480-2 · Cited by 65
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Alex, A. B., Pal, S. K., & Agarwal, N. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016642370 · Cited by 64
The genomic evolution of human prostate cancer
Mitchell, T., & Neal, D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.234 · Cited by 63
Prostate-specific membrane antigen theranostics: therapy with lutetium-177
Ferdinandus, J., Violet, J. A., Sandhu, S. K., & Hofman, M. S. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000486 · Cited by 58
Cabel, L., Loir, E., Gravis, G., Lavaud, P., Massard, C., Albiges, L. K., Baciarello, G., Loriot, Y., & Fizazi, K. S. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0232-7 · Cited by 57
Prostate cancer immunotherapy: where are we and where are we going?
Velasco, M. A. D., & Uemura, H. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000462 · Cited by 55
Gelato, K. A., Adler, D., Ocker, M., & Haendler, B. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1134490 · Cited by 54
Self-citationExploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer
Martin, S. K., & Kyprianou, N. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.03.001 · Cited by 54
Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
Pollard, M. E., Moskowitz, A. J., Diefenbach, M. A., & Hall, S. J. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.11.005 · Cited by 54
Immunotherapy for Prostate Cancer: Where We Are Headed
Schepisi, G., Farolfi, A., Conteduca, V., Martignano, F., Lisi, D. D., Ravaglia, G., Rossi, L., Menna, C., Bellia, S. R., Barone, D., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122627 · Cited by 54
Epigenetic Modifications in Prostate Cancer
Ngollo, M., Dagdemir, A., Karslı-Çeppioğlu, S., Judes, G., Pajon, A., Penault-Llorca, F. M., Boiteux, J., Bignon, Y., Guy, L., & Bernard-Gallon, D. J. (2014) · Epigenomics · doi:10.2217/epi.14.34 · Cited by 53
Wu, C., Jin, X., Yang, H. J., Yang, Y., He, Y., Ding, L., Pan, Y., Chen, S., Jiang, J., & Huang, H. (2015) · Oncotarget · doi:10.18632/oncotarget.6497 · Cited by 53
Khaja, A. S. S., Helczynski, L., Edsjö, A., Ehrnström, R. A., Lindgren, A., Ulmert, D., Andersson, T., & Bjartell, A. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026539 · Cited by 52
Therapeutic cancer vaccine survives biotech bust
Ledford, H. K. (2015) · Nature · doi:10.1038/nature.2015.16990 · Cited by 51
Exploiting Epigenetic Alterations in Prostate Cancer
Baumgart, S. J., & Haendler, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051017 · Cited by 47
Self-citationButler, M. S., Roshan‐Moniri, M., Hsing, M., Lau, D., Kim, A., Yen, P., Mroczek, M., Nouri, M., Lien, S. C., Axerio-Cilies, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17124 · Cited by 44
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0799-9 · Cited by 44
The molecular underpinnings of prostate cancer: impacts on management and pathology practice
Rodrigues, D. N., Boysen, G., Sumanasuriya, S., Seed, G., Marzo, A. M. D., & Bono, J. S. D. (2016) · The Journal of Pathology · doi:10.1002/path.4826 · Cited by 43
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
Choi, Y. J., Kim, H. S., Park, S. H., Kim, B. S., Kim, K. H., Lee, H. J., SONG, H. S., Shin, D., Lee, H. Y., Kim, H., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.438 · Cited by 42
Francini, E., & Sweeney, C. J. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.002 · Cited by 41
Zuber, V., GWAS, T. C., Bettella, F., Witoelar, A., Andreassen, O. A., Mills, I. G., & Urbanucci, A. (2017) · BMC Genomics · doi:10.1186/s12864-017-3620-y · Cited by 39
Sex steroids in the tumor microenvironment and prostate cancer progression
Boibessot, C., & Toren, P. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0493 · Cited by 39
PTEN loss and activation of K‐RAS and β‐catenin cooperate to accelerate prostate tumourigenesis
Jefferies, M. T., Cox, A. C., Shorning, B. Y., Méniel, V. S., Griffiths, D. F. R., Kynaston, H., Smalley, M. J., & Clarke, A. R. (2017) · The Journal of Pathology · doi:10.1002/path.4977 · Cited by 37
Small-Molecule Protein Tyrosine Kinase Inhibitors for the Treatment of Metastatic Prostate Cancer
Gallick, G. E., Corn, P. G., Zurita, A. J., & Lin, S.-H. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.161 · Cited by 36
Maeseneer, D. J. D., Praet, C. V., Lumen, N., & Rottey, S. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.01.008 · Cited by 35
van Soest, R. J., & de Wit, R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0543-9 · Cited by 35
Markowski, M. C., Marzo, A. M. D., & Antonarakis, E. S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1393518 · Cited by 35
Green, A. K., Corty, R. W., Wood, W. A., Meeneghan, M., Reeder-Hayes, K. E., Basch, E., Milowsky, M. I., & Dusetzina, S. B. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0432 · Cited by 34
Zhu, J., Liao, R., Su, C., Liang, D., Wu, J., Qiu, K., & Li, J. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1419871 · Cited by 34
Dalal, K., Che, M., Que, N. S., Sharma, A., Yang, R., Lallous, N., Borgmann, H., Özistanbullu, D., Tse, R., Ban, F., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0259 · Cited by 33
Targeted α Therapies for the Treatment of Bone Metastases
Zustovich, F., & Barsanti, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010074 · Cited by 33
Mulders, P., Santis, M. D., Powles, T. B., & Fizazi, K. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1707-3 · Cited by 32
Velasco, M. A. D., Kura, Y., Yoshikawa, K., Nishio, K., Davies, B. R., & Uemura, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7557 · Cited by 31
Functional and therapeutic significance of EZH2 in urological cancers
Liu, X., Wu, Q., & Li, L. (2017) · Oncotarget · doi:10.18632/oncotarget.16765 · Cited by 31
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer
Bryant, G., Wang, L., & Mulholland, D. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071542 · Cited by 31
A Novel Use of Olaparib for the Treatment of Metastatic Castration‐Recurrent Prostate Cancer
Martin, G. A., Chen, A. H., & Parikh, K. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2027 · Cited by 31
Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing
Jacoby, M. A., Duncavage, E. J., & Walter, M. J. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.006 · Cited by 29
DiPippo, V. A., Nguyen, H. M., Brown, L. G., Olson, W. C., Vessella, R. L., & Corey, E. (2015) · The Prostate · doi:10.1002/pros.23124 · Cited by 29
Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors
Feng, S., Shao, L., Castro, P. D., Coleman, I. M., Nelson, P. S., Smith, P. D., Davies, B. R., & Ittmann, M. (2016) · Oncotarget · doi:10.18632/oncotarget.14049 · Cited by 28
Lange, M., Laviec, H. S., Castel, H., Heutte, N., Leconte, A., Léger, I., Giffard, B., Capel, A., Dubois, M., Clarisse, B., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3534-8 · Cited by 25
Abiraterone in Metastatic Prostate Cancer
Gouw, S. C., & van der Bom, J. G. (2013) · Cited by 24
Summers, N., Vanderpuye-Orgle, J., Reinhart, M. L., Gallagher, M. E., & Sartor, O. A. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1341869 · Cited by 24
Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel
Fernández, O., Afonso, J., Vázquez‐Estévez, S., Campos, B., Lázaro, M., León‐Mateos, L., & Aparicio, L. M. A. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000045 · Cited by 21
Antibody-drug conjugates targeting prostate-specific membrane antigen
Olson, W. C., & Israel, R. J. (2014) · Frontiers in bioscience · doi:10.2741/4193 · Cited by 21
SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors
Dai, X., Wang, Z. P., & Wei, W. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1388973 · Cited by 21
Ipilimumab for the treatment of metastatic prostate cancer
Alaia, C., Boccellino, M., Zappavigna, S., Amler, E., Quagliuolo, L., Rossetti, S., Facchini, G., & Caraglia, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1420777 · Cited by 21
Preković, S., den Broeck, T. V., Moris, L., Smeets, E., Claessens, F., Joniau, S., Helsen, C., & Attard, G. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.020 · Cited by 17
Abiraterone in Metastatic Prostate Cancer.
James, N. D., Spears, M. R., & Sydes, M. R. (2017) · PubMed · doi:10.1056/nejmc1711029 · Cited by 16
Novel molecular aspects of prostate carcinogenesis
Meyer, H., Ahrens‐Fath, I., Sommer, A., & Haendler, B. (2003) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2003.11.001 · Cited by 14
Self-citationThe safety and efficacy of enzalutamide in the treatment of advanced prostate cancer
Ciccarese, C., Nobili, E., Grilli, D., Casolari, L., Rihawi, K., Gelsomino, F., Tortora, G., & Massari, F. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192468 · Cited by 14
Davies, M. J. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.5.3 · Cited by 12
Mikhaylenko, D. S., Ефремов, Г. Д., Strelnikov, V. V., Zaletaev, D. V., & Alekseev, B. Y. (2017) · Current Genomics · doi:10.2174/1389202917666161102095900 · Cited by 7
Vogelzang, N. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1345624 · Cited by 7
Cited by
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
Next generation organofluorine containing blockbuster drugs
Han, J., Remete, A. M., Dobson, L. S., Kiss, L., Izawa, K., Moriwaki, H., Soloshonok, V. A., & O’Hagan, D. (2020) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2020.109639 · Cited by 313
Joshi, M., Kim, J., D’Alessandro, A., Monk, E., Bruce, K., Elajaili, H., Nozik-Grayck, E., Goodspeed, A., Costello, J. C., & Schlaepfer, I. R. (2020) · Cancers · doi:10.3390/cancers12113431 · Cited by 54
Metadata
- Authors
- Nevedomskaya, E., Baumgart, S. J., & Haendler, B.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-05-04
- Volume
- 19
- Issue
- 5
- Pages
- 1359
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2799375096
- Cited by
- 254
- References
- 174
- FWCI
- 21.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.